Literature DB >> 8637302

Early intervention in chronic obstructive pulmonary disease. A review of the Lung Health Study results.

R E Kanner1.   

Abstract

The major findings of the LHS that have been reported thus far are that an effective smoking cessation program can be developed that can produce more than a 20% success rate in getting smokers to give up the habit permanently, and that by stopping smoking, individuals with early COPD benefit by having an initial improvement in lung function and a slowing of the annual loss of their FEV1. The use of a bronchodilator has a short-term effect in improving the FEV1, but it does not affect long-term changes in lung function. AHR is common in patients with mild-to-moderate COPD. The reward for a smoker to give up the habit is an initial gain in FEV1 and a subsequent close to normal annual rate of decline of this pulmonary function parameter. These results should provide a positive incentive for smokers to quit and thereby decrease the morbidity and mortality caused by the use of tobacco.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8637302     DOI: 10.1016/s0025-7125(05)70452-1

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  8 in total

Review 1.  Group behaviour therapy programmes for smoking cessation.

Authors:  Lindsay F Stead; Allison J Carroll; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2017-03-31

2.  Outcome-related, Auxiliary Variable Sampling Designs for Longitudinal Binary Data.

Authors:  Jonathan S Schildcrout; Enrique F Schisterman; Melinda C Aldrich; Paul J Rathouz
Journal:  Epidemiology       Date:  2018-01       Impact factor: 4.822

3.  Genome-Wide Association Study Identification of Novel Loci Associated with Airway Responsiveness in Chronic Obstructive Pulmonary Disease.

Authors:  Nadia N Hansel; Peter D Paré; Nicholas Rafaels; Don D Sin; Andrew Sandford; Denise Daley; Candelaria Vergara; Lili Huang; W Mark Elliott; Chris D Pascoe; Bryna A Arsenault; Dirkje S Postma; H Marike Boezen; Yohan Bossé; Maarten van den Berge; Pieter S Hiemstra; Michael H Cho; Augusto A Litonjua; David Sparrow; Carole Ober; Robert A Wise; John Connett; Enid R Neptune; Terri H Beaty; Ingo Ruczinski; Rasika A Mathias; Kathleen C Barnes
Journal:  Am J Respir Cell Mol Biol       Date:  2015-08       Impact factor: 6.914

4.  Biomedical risk assessment as an aid for smoking cessation.

Authors:  Carole Clair; Yolanda Mueller; Jonathan Livingstone-Banks; Bernard Burnand; Jean-Yves Camain; Jacques Cornuz; Myriam Rège-Walther; Kevin Selby; Raphaël Bize
Journal:  Cochrane Database Syst Rev       Date:  2019-03-26

Review 5.  Cigaret smoking and the lung.

Authors:  S Murin; J Hilbert; S J Reilly
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 10.817

6.  Genome-wide study identifies two loci associated with lung function decline in mild to moderate COPD.

Authors:  Nadia N Hansel; Ingo Ruczinski; Nicholas Rafaels; Don D Sin; Denise Daley; Alla Malinina; Lili Huang; Andrew Sandford; Tanda Murray; Yoonhee Kim; Candelaria Vergara; Susan R Heckbert; Bruce M Psaty; Guo Li; W Mark Elliott; Farzian Aminuddin; Josée Dupuis; George T O'Connor; Kimberly Doheny; Alan F Scott; H Marike Boezen; Dirkje S Postma; Joanna Smolonska; Pieter Zanen; Firdaus A Mohamed Hoesein; Harry J de Koning; Ronald G Crystal; Toshiko Tanaka; Luigi Ferrucci; Edwin Silverman; Emily Wan; Jorgen Vestbo; David A Lomas; John Connett; Robert A Wise; Enid R Neptune; Rasika A Mathias; Peter D Paré; Terri H Beaty; Kathleen C Barnes
Journal:  Hum Genet       Date:  2012-09-18       Impact factor: 4.132

Review 7.  Effectiveness of biomedical risk assessment as an aid for smoking cessation: a systematic review.

Authors:  Raphaël Bize; Bernard Burnand; Yolanda Mueller; Jacques Cornuz
Journal:  Tob Control       Date:  2007-06       Impact factor: 7.552

Review 8.  Systematic review of the evidence relating FEV1 decline to giving up smoking.

Authors:  Peter N Lee; John S Fry
Journal:  BMC Med       Date:  2010-12-14       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.